Reliability of reverse transcription-polymerase chain reaction (RT- PCR)-based assays for the detection of circulating tumour cells: A quality- assurance initiative of the EORTC Melanoma Cooperative Group

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 750-753

  Keilholz, U ^a   Willhauck, M ^d   Rimoldi, D ^b   Brasseur, F ^c   Dummer, W ^d   Rass, K ^d   De Vries, T ^d   Blaheta, J ^d   Voit, C ^d   Lethe B ^c   Burchill, S ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d NONE

Author keywords

Melanoma; PCR; Quality assurance; RT PCR; Tyrosinase

Indexed keywords

ARTICLE; CANCER CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; MELANOMA; NORMAL HUMAN; OCCULT CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DNA, NEOPLASM; HUMANS; MELANOMA; NEOPLASM CIRCULATING CELLS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 0032055246     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10105-8     Document Type: Article

References (24)

1. 1. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338, 1227-1229.
2. 2. Brossart P, Keilholz U, Willhauck M, et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993, 101, 887-889.
3. 3. Brossart P, Keilholz U, Scheibenbogen C, Möhler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother 1994, 15, 38-41.
4. 4. Curry BJ, Smith MJ, Hersey P. Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Res 1996, 6, 45-54.
5. 5. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995, 72, 155-159.
6. 6. Battyani Z, Grob J, Xerri L, et al. PCR detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995, 131, 443-447.
7. 7. Hoon DSB, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995, 13, 2109-2116.
8. 8. Brossart P, Schmier J, Krüger S, et al. A PCR-based semi-quantitative assessment of malignant cells in peripheral blood. Cancer Res 1995, 55, 4065-4068.
9. 9. Kunter U, Buer J, Probst M, et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996, 88, 590-594.
10. 10. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction (RT-PCR) correlates with stage and prognosis in malignant melanoma. Proc ASCO 1996, 433.
11. 11. Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993, 341, 722-724.
12. 12. Keilholz U (for the EORTC Melanoma Cooperative Group). Diagnostic PCR in melanoma: methods and quality assurance. Eur J Cancer 1996, 32A, 1661-1663.
13. 13. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 1976, 73, 3278-3282.
14. 14. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162, 156.
15. 15. Brichard VG, Herman J, Van Pel A, et al. A tyrosinase non-apeptide presented by HLA B44 is recognized on a human melanoma by autologous cytolytic lymphocytes. Eur J Immunol 1996, 26, 224-230.
16. 16. Battyani Z, Xerri L, Hassoun J, Bonerandi JJ, Grob JJ. Tyrosinase gene expression in human tissues. Pigment Cell Res 1993, 6, 400-406.
17. 17. Buzaid AC, Balch CM. Polymerase chain reaction of melanoma in peripheral blood: too early to assess clinical value. J Natl Cancer Inst 1996, 88, 569-570.
18. 18. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 1992, 52, 6110-6112.
19. 19. Israeli RS, Miller WH, Su SL, et al. Sensitive nested reserve transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994, 54, 6306-6310.
20. 20. Katz AE, Olsson CA, Raffo A, et al. Molecular staging of prostate cancer with the use of an enhanced RT-PCR assay. Urology 1994, 43, 765-775.
21. 21. Ghossein RA, Scher HI, Gerald WL, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995, 13, 1195-1200.
22. 22. Jaakkola S, Vornanen T, Leinonen J, Rannikko S, Stenman UH. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. Clin Chem 1995, 41, 182-186.
23. 23. Jackson DP, Hayden JD, Quirke P. PCR. A Practical Approach, McPherson MJ, Quirke P, Taylor GR, eds. Oxford, IRL Press, 1991, 29-50.
24. 24. Keilholz U, Willhauck M, Scheibenbogen C, de Vries T, Burchill S (for the EORTC-Melanoma Cooperative Group). Polymerase chain reaction detection of circulating tumour cells. Melanoma Res 1997, 7(Suppl. 2), S133-S141.